Unlock instant, AI-driven research and patent intelligence for your innovation.

Quinoline and quinoxaline compounds

A compound, polymer technology, applied in the Lck tyrosine kinase activity inhibitor of quinoxaline can be used in the field of treatment, can solve the problems such as no reports

Inactive Publication Date: 2008-05-28
AVENTIS PHARMA SA (US)
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

No Lck inhibitors have been reported for quinoline or quinoxaline based compounds

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Quinoline and quinoxaline compounds
  • Quinoline and quinoxaline compounds
  • Quinoline and quinoxaline compounds

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0054] Preferred compounds of the invention are compounds of formula I as defined below, wherein R 1a is an optionally substituted lower alkoxy group, an optionally substituted monocyclic cycloalkoxy group, an optionally substituted heterocyclylcarbonyloxy group, or an optionally substituted monoepoxyheteroheterooxyloxy group; more preferably R 1a is methoxy, ethoxy, 2-(ethoxy)ethoxy, 2-(4-morpholinyl)ethoxy or furyloxy.

[0055] Further preferred compounds of the invention are compounds of formula I as defined below, wherein R 1b is hydrogen, optionally substituted lower alkoxy, optionally substituted monocyclic cycloalkoxy, optionally substituted or optionally substituted lower alkoxy; still more preferably R 1b is methoxy or ethoxy.

[0056] Further preferred compounds of the invention are compounds of formula I as defined below, wherein R 1a and R 1b is lower alkoxy; more preferably lower alkoxy is methoxy or ethoxy.

[0057] Further preferred compounds of the inventi...

Embodiment 1

[0157] Example 1 2-(3-fluorophenylamino)-6,7-diethoxyquinoxaline

[0158] To 0.25 g (0.989 mmol) of 2-chloro-6,7-diethoxyquinoxaline was added 2 ml of m-fluoroaniline. The mixture was heated at 120° C. overnight under nitrogen atmosphere. The obtained mixture was separated by chromatography (30:1 CH 2 Cl 2 : EtOH), a partially purified product was obtained. The solid was triturated with ethyl acetate to give 0.175 g of product as a brownish yellow solid, 54.1% yield (m.p. 193°C).

[0159] Elemental Analysis C 18 h 18 N 3 o 2 F 0.25H 2 o

[0160] Calculated: C, 65.15; H, 5.62; N, 12.66;

[0161] Found: C, 65.30; H, 5.30; N, 12.41.

Embodiment 2

[0162] Example 2 2-anilino-6-methoxyquinoxaline hydrochloride

[0163] To 2-chloro-6-methoxyquinoxaline (0.93 g, 4.8 mmol) was added aniline (1.3 ml, 14.3 mmol) under argon atmosphere. The reaction mixture was heated at 120°C for 2 hours, then at 150°C for 1.5 hours. The mixture was cooled and CH was added 2 Cl 2 . The obtained suspension was stirred, the orange solid was filtered off and washed with CH 2 Cl 2 / Et 2 O washed, then vigorously stirred in water for 40 min, filtered, and washed with Et 2 O washes afforded a bright yellow solid.

[0164] The following compounds were prepared analogously starting from appropriate starting materials.

[0165] 2-(3-Carbamoylphenylamino)-6-methoxyquinoxaline, m.p. 2.47°C. Elemental Analysis C 16 h 14 N 4 o 2 0.25H 2 O, calculated: C, 64.31; H, 4.89; N, 18.75;

[0166] Found values: C, 64.24; H, 5.04; N, 18.75;

[0167] 2-(2-Fluorophenylamino)-6,7-diethoxyquinoxaline, m.p. 184°C. Elemental Analysis C 18 h 18 FN 3 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
boiling pointaaaaaaaaaa
Login to View More

Abstract

This invention is directed to quinoline / quinoxaline compounds which inhibit platelet-derived growth factor tyrosine kinase and / or Lck tyrosine, kinase, to pharmaceutical compositions comprising these compounds, and to the use fo these compounds for treating a patient suffering from or subject to disorders / conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and / or T cell activation and proliferation.

Description

[0001] Related application introduction [0002] This application is a continuation of U.S. Patent Application No. 09 / 198,716, filed November 24, 1998, which in turn is a continuation of International Patent Application No. PCT / US98 / 10999, filed May 28, 1998 Continuation of International Patent Application, a continuation of now abandoned U.S. Patent Application Serial No. 08 / 972,614, filed November 18, 1997, now abandoned, filed May 18, 1997 Continuation of US Patent Application Serial No. 08 / 864,455. Background of the invention [0003] 1. field of invention [0004] The present invention relates to the use of quinoline / quinoxaline compounds useful as protein tyrosine kinase inhibitors (TKIs) to inhibit cell proliferation and / or cell matrix production and / or cell motility (chemotaxis) and / or T cells activation and proliferation. [0005] Cell signaling is mediated through interaction systems, including cell-cell contacts or cell-matrix contacts or extracellular recepto...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D241/44C07D215/20C07D215/38C07D405/12A61K31/47A61K31/495A61P35/00A61K31/498A61P9/00A61P29/00A61P43/00C07D241/52C07D241/54C07D403/04
CPCC07D403/04C07D215/20C07D215/38C07D405/12C07D241/54C07D241/52C07D241/44A61P29/00A61P35/00A61P43/00A61P9/00C07D241/42C07D453/06
Inventor M·R·梅耶尔斯A·P·斯巴达P·E·伯森斯M·P·玛古伊勒
Owner AVENTIS PHARMA SA (US)